한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제28권1호
  • /
  • Pages.53-58
  • /
  • 2024
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Incidental double duct sign: Should we be worried? Results from a long-term follow-up study

  • Lu Yao (Department of HPB Surgery, University of Plymouth) ;
  • Hoda Amar (Department of HPB Surgery, University of Plymouth) ;
  • Somaiah Aroori (Department of HPB Surgery, University of Plymouth)
  • 투고 : 2023.05.17
  • 심사 : 2023.07.05
  • 발행 : 2024.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds/Aims: Double duct sign (DDS) (dilated common bile and pancreatic duct) is synonymous with pancreatic head/peri-ampullary tumor (PHPAT). There is limited evidence on whether incidental DDS (I-DDS) is associated with an increased risk of malignancy. This study aimed to evaluate 5-year outcomes of I-DDS. Methods: Patients were categorized according to their risk of malignancy. 'Low-risk' patients, including those with I-DDS between 2010 and 2015, were analyzed in this study. The primary outcome was incidence of PHPAT within five years of identification of DDS. Histology results from endoscopic ultrasound-guided biopsy were considered diagnostic. Secondary outcomes were incidence of benign causes, extent of follow-up investigations, and clinical indicators of malignancy in patients with DDS. Results: Among 103 patients with DDS, 20 had I-DDS. Subsequent follow-up of these 20 patients found no patient with PHPAT, two (10%) patients with chronic pancreatitis, and 18 (90%) patients with no cause found. The median follow-up duration for 'low-risk' patients was 7.3 years (range, 6-11 years). The mean number of follow-up investigations per patient was two (range, 0-9). Investigations included computed tomography (n = 27), magnetic resonance cholangiopancreatography (n = 23), endoscopy (n = 16), and ultrasound (n = 14). Patients with jaundice were more likely to have malignancy (p < 0.01). Those with abdominal pain were more likely to have a benign cause (p < 0.01). Hyperbilirubinemia and/or deranged liver enzymes and raised CA19-9 were more likely to be associated with PHPAT (p < 0.01). Conclusions: Patients with I-DDS have a low risk of developing PHPAT within five years.

키워드

과제정보

The authors thank Plymouth University Hospital Hepato-Pancreatico-Biliary performance team for obtaining the patient list.

참고문헌

  1. Ahualli J. The double duct sign. Radiology 2007;244:314-315.  https://doi.org/10.1148/radiol.2441041978
  2. Yadav P, Lal H. Double duct sign. Abdom Radiol (NY) 2017;42:1283-1284.  https://doi.org/10.1007/s00261-016-0979-1
  3. Sinha R, Gardner T, Padala K, Greenaway JR, Joy D. Double-duct sign in the clinical context. Pancreas 2015;44:967-970.  https://doi.org/10.1097/MPA.0000000000000372
  4. Baillie J, Paulson EK, Vitellas KM. Biliary imaging: a review. Gastroenterology 2003;124:1686-1699.  https://doi.org/10.1016/S0016-5085(03)00390-1
  5. Cohen J, Sawhney MS, Pleskow DK, Chuttani R, Patel NJ, Sheridan J, et al. Double-duct sign in the era of endoscopic ultrasound: the prevalence of occult pancreaticobiliary malignancy. Dig Dis Sci 2014;59:2280-2285.  https://doi.org/10.1007/s10620-014-3133-3
  6. Wolske KM, Ponnatapura J, Kolokythas O, Burke LMB, Tappouni R, Lalwani N. Chronic pancreatitis or pancreatic tumor? a problem-solving approach. Radiographics 2019;39:1965-1982.  https://doi.org/10.1148/rg.2019190011
  7. Menges M, Lerch MM, Zeitz M. The double duct sign in patients with malignant and benign pancreatic lesions. Gastrointest Endosc 2000;52:74-77.  https://doi.org/10.1067/mge.2000.105775
  8. Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 2004;182:897-903.  https://doi.org/10.2214/ajr.182.4.1820897
  9. Krishna N, Tummala P, Reddy AV, Mehra M, Agarwal B. Dilation of both pancreatic duct and the common bile duct on computed tomography and magnetic resonance imaging scans in patients with or without obstructive jaundice. Pancreas 2012;41:767-772.  https://doi.org/10.1097/MPA.0b013e31823ba536
  10. Malik S, Kaushik N, Khalid A, Bauer K, Brody D, Slivka A, et al. EUS yield in evaluating biliary dilatation in patients with normal serum liver enzymes. Dig Dis Sci 2007;52:508-512.  https://doi.org/10.1007/s10620-006-9582-6
  11. Coss A, Enns R. The investigation of unexplained biliary dilatation. Curr Gastroenterol Rep 2009;11:155-159.  https://doi.org/10.1007/s11894-009-0024-4
  12. Agarwal B, Krishna NB, Labundy J, Safdar R, Akduman EI. EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct. Gastrointest Endosc 2008;68:237-242.  https://doi.org/10.1016/j.gie.2008.01.026
  13. Thomasset SC, Saunders D, Holland A, Dennison AR, Garcea G. Malignant biliary strictures in patients with a normal bilirubin and/or normal liver enzymes. HPB (Oxford) 2015;17:969-974.  https://doi.org/10.1111/hpb.12468
  14. Natalucci V, Virgili E, Calcagnoli F, Valli G, Agostini D, Zeppa SD, et al. Cancer related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients 2021;13:482. 
  15. McGuigan A, Kelly P, Turkington R, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2018;24:4846-4861.  https://doi.org/10.3748/wjg.v24.i43.4846
  16. Paluri RK, Kasi A. Ampullary Cancer [Internet]. StatPearls Publishing 2022 [cited 2022 Dec 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555958/. 
  17. Gardner T, Padala K, Sinha R, Greenaway J, Joy D. PTH-105 how ominous is the "double-duct" sign?: a single centre experience. Gut 2014;63:A257. 
  18. Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer HP, Beger HG. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987;2:398-403.  https://doi.org/10.1097/00006676-198707000-00006
  19. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31:164-169.  https://doi.org/10.1016/j.ejso.2004.09.007
  20. Mizuide M, Ryozawa S, Fujita A, Ogawa T, Katsuda H, Suzuki M, et al. Complications of endoscopic ultrasound-guided fine needle aspiration: a narrative review. Diagnostics (Basel) 2020;10:964. 
  21. National Institute for Health and Care Excellence (NICE). The Spy-Glass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system [MIB21] [Internet]. NICE 2015 [cited 2022 Dec 22]. Available from: https://www.nice.org.uk/advice/mib21.